From: Endobronchial one-way valves for treatment of persistent air leaks: a systematic review
First author, year [Article no.] | Publication type | No. of patients, sex(M/F) | Age (years) | Underlying disease (n/N) | Previous interventions (n/N) | Duration of air leak before valve placement | Location of endobronchial one-way valves (n/N) | Type of endobronchial one-way valves; No. of valves used |
---|---|---|---|---|---|---|---|---|
Travaline, 2009 [49] | Retrospective study | 40 (25/15) | Mean ± SD: 60 ± 14 | Cancer (12/40), COPD(12/40), pneumonia (3/40), rheumatoid arthritis(2/40), tuberculosis(1/40), trauma(1/40), aspergilloma(1/40), bronchiectasis (1/40), cor pulmonale(1/40), lung transplantation (1/40), multiple comorbidities (1/40) | chest tube (39/40), Eloesser flap (1/40), Blood patch (3/40), wedge resection (1/40), pleurodesis (1/40) | Median: 20 days; Interquartile range [IQR]: 15 to 45 days | RUL (11/40), RML (3/40), RLL (3/40), LUL (11/40), LLL(5/40), RUL and RLL (1/40), RLL and RML (1/40), RUL and LUL (1/40); | Zephyr®; Mean ± SD: 2.9 ± 1.9 |
Gillespie, 2011 [50] | Retrospective study | 7 (4/3) | Median:58; Range: 17 to 60 | Emphysema (5/7), neoplasia (3/7), pulmonary embolism (2/7), radiation fibrosis (1/7), fungal infection (1/7), empyema (1/7) | surgical interventions (6/7); pleurodesis or pleurectomy (4/7) | Median: 4Â weeks; Range: 2Â weeks to 5 months | LUL (4/31); LLL (6/31); RUL (7/31); LUL and LLL (14/31) | IBV Valve; Median: 3.5 |
Firlinger, 2013 [51] | Prospective study | 13 | Not specified | Empyema (4/13), pulmonary metastasis (1/13), pleural mesothelioma (3/13), pneumothorax (2/13), lung cancer (2/13), bronchiectasis (1/13) | Chest tube (4/13), lobectomy (3/13), decortication (2/13), radical pleurectomy (3/13), pleurodesis (1/13) | Median: 17 days; Range: 8–31 days | LUL (2/19), LLL (5/19), RUL (10/19), RLL (2/19) | IBV Valve (13/19) and Zephyr® (6/19), Mean ± SD: 1.4 ± 0.7 |
Reed, 2015 [52] | retrospective study | 21 (11/10) | Range: 16Â months to 70Â years | postoperative (8/21), pneumothorax (11/21), cavitary lung infection (3/21), post-pneumonectomy bronchopleural fistula (2/21), COPD(3/21), Pneumonia(4/21), Rheumatoid lung disease(1/21), ARDS after cardiac surgery (121/), Lung cancer(1/21), Refractory AML(21/), Hypoxic cardiac arrest(121/), Refractory multiple myeloma(1/21) | Chest tube(18/21), Pleurodesis(1/21), Decortication(1/21), intercostal muscle flap coverage (2/21) | Median: 8Â days; Mean, 26Â days; Range: 1 to 192Â days | RUL(20/88), RML(8/88), RLL(8/88), LUL(21/88), Lingula(6/88), LLL(12/88), 2 patients not specified | IBV Valve; Median:3; Range: 1 to 12 |
Dooms, 2014 [53] | prospective study | 10 (9/1) | Median:67; Range: 46 to 75 | Lung cancer (10/10) | Chest tube (10/10), chemical pleurodesis (not specified) | Median: 7Â days; Range: 7 to 13Â days | RLL (17/42), RUL (10/42), LLL (15/42) | IBV Valve; Median: 4; Range:1 to 9 |
Cordovilla, 2015 [54] | prospective study | 8 (7/1) | Mean: 68.5 Range:28 to 85 | severe pulmonary emphysema(7/8), respiratory failure (5/8), thrombopenia (1/8), ischemic heart disease (1/8) cancer(1/8) | Chest tube (8/8) | Median: 15.5 days | RLL (2/9), Lingula (1/9), RUL (3/9), LUL (1/9), LLL (2/9) | IBV valves(8/9) and Zephyr® (1/9); Median: 2; Range: 1 to 4 |
Hance, 2015 [55] | retrospective study | 14 (10/4) | Mean: 60 | non-small cell lung cancer (4/14), diffuse interstitial lung disease (1/14), cytomegalovirus pneumonitis (1/14), COPD (4/14), histoplasmosis (1/14), pneumonia (1/14), pulmonary nodule (1/14), idiopathic pulmonary fibrosis (1/14), aspergillosis (1/14), cystic fibrosis (1/14), metastatic mesothelioma (1/14), spontaneous pneumothoraxes (3/14) | Chest tube (14/14) | Mean: 21.6 days; Median: 18 days; | Not specified | IBV Valve (14); Median: 2; Range: 1–8 |
Podgaetz, 2015 [56] | retrospective study | 19 (12/7) | Median: 60; Mean:60.4;Range: 38–90 | Osteosarcoma (1/19), COPD (9/19), angiosarcoma (1/19), cryptogenic organizing pneumonia (1/19), pancreatic cancer (1/19), interstitial lung disease (2/19) | Chest tube (19), Chemical pleurodesis (2), Blood patch (1) | Median: 9 days; Mean: 12.8 days; Range: 2–8 days | LUL + lingula (1), RUL (5), LUL (7), RLL (3), RML (1), Lingula (2) | IBV Valve (72); Median: 4; Range: 2–6 |
Bakhos, 2016 [57] | prospective study | 11 (9/2) | Mean ± SD: 65 ± 15; Range: 33–83 | Lung cancer (5/11), mesothelioma (1/11), COPD (6/11), coccidiomycosis (1/11), interstitial lung disease (2/11) | Chest tube (11) | Mean ± SD:16 ± 12 days | RLL (3), RUL (3), LUL (3), RML (1), RUL and RML (1) | IBV Valve; Median: 2; Range: 1–4 |
Podgaetz, 2016 [14] | prospective study | 13 (9/4) | Median: 60; Mean:61.9;Range: 38–90 | Osteosarcoma (1/13), COPD (7/13), Iatrogenic (4/13), Postoperative (2/13), Angiosarcoma (1/13), pancreatic cancer (1/13), cryptogenic organizing pneumonia(1/13) | Chest tube (13) | Median: 9 days; Mean: 14.9 days; Range: 2–88 days | LUL (5), Lingual (2), RUL (4), RLL (2), RML (1) | IBV Valve; Median: 4; Range: 2–6 |